Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck

Read MoreHide Full Article

For Immediate Release

Chicago, IL – December 30, 2019 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie (ABBV - Free Report) , Abbott Labs (ABT - Free Report) , Allergan (AGN - Free Report) , Johnson & Johnson (JNJ - Free Report) and Merck & Co. (MRK - Free Report) .

Here are highlights from Friday’s Analyst Blog:

3 Dividend-Paying Large-Cap Pharma Stocks to Consider for 2020

The strong end to the year has helped lift the S&P 500 over 28% in 2019. But investors now wonder what might be in store for equities in the upcoming year.

Let’s take a look at a few stocks in the large cap pharma industry, which ranks in the top 9% of our over 250 Zacks industries, that look poised to have a strong 2020.

AbbViehas been able to outpace the S&P 500 since its spinoff from Abbott Labs in early 2013. AbbVie’s cash cow is Humira, which accounts for about 60% of its total revenue. The company’s dependence on Humira has been a cause for concern with many investors, as its patent expired in Europe this year. This caused the decline in Humira sales.

The firm’s US patent is also scheduled to expire in 2023. But AbbVie has started to strategically prepare itself for the emergence of biosimilars in the US market. The company currently boasts a diverse portfolio of products that consists of oncology medicines such as Imbruvica and Venclexta and immunology products like Skyrizi and Rinvoq.

In addition, AbbVie expects its Allergan acquisition to close by the end of the first quarter of 2020, which will further diversify its portfolio. AbbVie has also been an income investor-friendly stock as it has averaged over a 24% annual hike to its dividend since its inception.

ABBV stock currently sports a dividend with a hefty 4.76% yield and trades at 10X its forward earnings, which is below the industry average of 15X. Our consensus fiscal 2020 estimates call for earnings to grow over 5.2% to $9.41 per share and for net revenue to increase 8.3% to $36.1 billion.

Johnson & Johnsonis the largest pharmaceutical company in the world in terms of market cap. The pharma titan has been hit recently with an onslaught of legal headwinds from its alleged involvement in the opioid crisis to its alleged harmful talcum powder. However, despite the recent litigation, the firm’s diversified operations in the healthcare industry are unrivaled. Johnson & Johnson’s pharmaceutical portfolio is well diversified across the oncology and immunology fields.

In the immunology segment, the firm’s key growth drivers are Stelara and Tremfya, which climbed 30% and 69% in the third quarter, respectively. Meanwhile, Imbruvica is at the forefront of the company’s oncology portfolio and saw an increase of 31% in the third quarter.

In addition to JNJ’s impressive pharmaceutical portfolio, the firm also operates in other channels such as medical devices and its consumer segment, which includes the popular skin care treatment Neutrogena. This large cap pharma stock also boasts a dividend with a solid 2.61% yield that has been increased for the past 57 years.

Our fiscal 2020 estimates forecast a top-line rally of 4.2% to $85.5 billion and a bottom-line jump of 4.8% to $9.08 per share. Johnson & Johnson has an average EPS surprise of 4.27% over the past four quarters and sits at a Zacks Rank #2 (Buy).

Merck & a large cap pharma stock that has put together a solid year as its shares have risen over 19% and have outpaced the industry’s 12% YTD run. This pharmaceutical giant is currently focused on the oncology realm with its crown-jewel, Keytruda. The drug has been approved for a plethora of cancers including lung cancer and melanoma. The company’s top-line is also driven by its vaccine business, which includes its HPV vaccine Gardasil/Gardasil 9.

In the most recent quarter, Keytruda sales soared 62% to roughly $3.1 billion and Gardasil/Gardasil 9 sales climbed 26% to $1.32 billion. Keytruda is expected to be Merck’s bread and butter for the foreseeable future as the drug is projected to become the world's bestselling drug by 2025.

Merck also offers a dividend with a healthy 2.67% yield. The stock currently trades at about 16X its forward earnings, which is just below the S&P 500 average of 18X. Our fiscal 2020 estimates anticipate an almost 6% top-line hike to $49.8 billion and a bottom-line jump of over 6% to $5.49 per share. MRK’s earnings estimate revisions have trended higher, helping earn the stock a Zacks Rank #2 (Buy).

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.

This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.

See their latest picks free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                            

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Published in